(Q38857169)

https://doi.org/10.1080/1120009X.2023.2296759

7 September 2017

1 reference

9 February 2024

title

Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line (English)

1 reference

7 September 2017

0 references

Elham Bakhtiari

1 reference

7 September 2017

Azar Hosseini

series ordinal

1 reference

7 September 2017

Mohammad Taher Boroushaki

series ordinal

1 reference

7 September 2017

Seyed Hadi Mousavi

series ordinal

1 reference

7 September 2017

publication date

3 July 2015

1 reference

7 September 2017

published in

Journal of Chemotherapy

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

314-320

1 reference

Anticancer polysaccharides from natural resources: a review of recent research

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Genotoxic evaluation of five Angiotesin II receptor blockers: in vivo and in vitro micronucleus assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Angiotensin receptors: a new role in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

NF-kappaB and cancer-identifying targets and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

NF-kappaB and IKK as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Olmesartan, an AT1 Antagonist, Attenuates Oxidative Stress, Endoplasmic Reticulum Stress and Cardiac Inflammatory Mediators in Rats with Heart Failure Induced by Experimental Autoimmune Myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Captopril as a potential inhibitor of lung tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Imatinib resistance in multidrug-resistant K562 human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947815Y.0000000055

Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1179/1973947815Y.0000000055

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1179/1973947815Y.0000000055

BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1179/1973947815Y.0000000055

Identifiers

DOI

10.1179/1973947815Y.0000000055

1 reference

7 September 2017

1 reference